All In Biotech

Drug Trial Radar · NCT04647643

Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease

Last checked: Nov 19, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8,000

Actual

Start

Nov 20, 2020

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Lahey ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Evaluation System for health Technology Coordinating Center; Society for Vascular Surgery Patient Safety Organization
First posted
Dec 1, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatment with paclitaxel-based endovascular devices (PED) has become a common treatment option for patients with peripheral artery disease (PAD) involving the femoral-popliteal artery. However, an aggregate level meta-analysis identified an association between the use of PED and increased all-cause mortality at both two and five-year follow-up intervals, though there are significant limitations of these analyses. Exploration of real-world data has been suggested as a means to further investigate the safety of PED. The current study explores the association of PED and mortality in real-world data using U.S. commercial claims from the FAIR Health data warehouse.

Conditions

  • Peripheral Arterial Disease

Interventions

  • PaclitaxelDrug

    Paclitaxel to treat peripheral arterial disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: 4 years post intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lahey Clinic, Inc

    Burlington, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.